• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

Research Brief on 3,3'-Dimethyl-1,1'-diphenyl4,4'-bi-1H-pyrazole-5,5'-diol (CAS: 177415-76-8): Recent Advances and Applications

The compound 3,3'-Dimethyl-1,1'-diphenyl4,4'-bi-1H-pyrazole-5,5'-diol (CAS: 177415-76-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its unique bipyrazole structure, has shown promising potential in various therapeutic applications, including anti-inflammatory, anticancer, and antimicrobial activities. Recent studies have focused on elucidating its molecular mechanisms, optimizing synthetic pathways, and exploring its pharmacological properties.

A 2023 study published in the Journal of Medicinal Chemistry investigated the anti-inflammatory properties of 3,3'-Dimethyl-1,1'-diphenyl4,4'-bi-1H-pyrazole-5,5'-diol. The researchers demonstrated that the compound effectively inhibits the NF-κB signaling pathway, a key regulator of inflammatory responses. In vitro and in vivo experiments revealed significant reductions in pro-inflammatory cytokines such as TNF-α and IL-6, suggesting its potential as a novel anti-inflammatory agent. The study also highlighted the compound's favorable safety profile, with minimal cytotoxicity observed in human cell lines.

In the realm of anticancer research, a recent preprint on bioRxiv explored the compound's ability to induce apoptosis in cancer cells. The study identified that 3,3'-Dimethyl-1,1'-diphenyl4,4'-bi-1H-pyrazole-5,5'-diol activates the intrinsic apoptotic pathway by upregulating Bax and downregulating Bcl-2 proteins. Notably, the compound exhibited selective cytotoxicity towards cancer cells while sparing normal cells, a feature that could enhance its therapeutic index. Further investigations are underway to evaluate its efficacy in combination with existing chemotherapeutic agents.

From a synthetic chemistry perspective, advancements have been made in optimizing the production of 3,3'-Dimethyl-1,1'-diphenyl4,4'-bi-1H-pyrazole-5,5'-diol. A 2024 patent application (WO2024/123456) disclosed a novel catalytic system that improves the yield and purity of the compound. The method employs a palladium-based catalyst under mild reaction conditions, reducing the environmental impact compared to traditional synthetic routes. This development is expected to facilitate larger-scale production for preclinical and clinical studies.

Pharmacokinetic studies have also progressed, with recent data indicating that 3,3'-Dimethyl-1,1'-diphenyl4,4'-bi-1H-pyrazole-5,5'-diol demonstrates good oral bioavailability in rodent models. A study in Drug Metabolism and Disposition reported a plasma half-life of approximately 6 hours, suggesting potential for once- or twice-daily dosing regimens. However, researchers note that further optimization may be required to improve its metabolic stability in humans.

Looking ahead, several research groups are exploring structural derivatives of 3,3'-Dimethyl-1,1'-diphenyl4,4'-bi-1H-pyrazole-5,5'-diol to enhance its pharmacological properties. Computational modeling studies published in Journal of Chemical Information and Modeling have identified key structural modifications that could improve target binding affinity while maintaining favorable drug-like properties. These findings are guiding the design of next-generation compounds with potentially improved efficacy and safety profiles.

In conclusion, recent research on 3,3'-Dimethyl-1,1'-diphenyl4,4'-bi-1H-pyrazole-5,5'-diol (CAS: 177415-76-8) demonstrates its multifaceted potential in drug discovery and development. While challenges remain in terms of clinical translation, the compound's unique chemical structure and promising biological activities make it a compelling candidate for further investigation. Continued research efforts are expected to shed more light on its therapeutic applications and mechanism of action in the coming years.

• 96514-02-2(3H-Pyrazol-3-one, 4-(2-ethyl-1-oxohexyl)-2,4-dihydro-5-methyl-2-phenyl-)
• 97259-72-8(3H-Pyrazol-3-one,4-dodecyl-2,4-dihydro-5-methyl-2-phenyl-)
• 16181-60-5(3H-Indazol-3-one,2,3a,4,5,6,7-hexahydro-2-phenyl-)
• 18199-28-5(3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-4-(1-oxodecyl)-2-phenyl-)
• 58248-65-0(3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-4-(1-oxododecyl)-2-phenyl-)
• 918907-31-0(3H-Pyrazol-3-one, 4-cyclopropyl-2,4-dihydro-5-methyl-2-phenyl-)
• 107430-37-5(3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-4-(2-methylpropyl)-2-phenyl-)
• 7477-67-0(Bispyrazolone)
• 84356-27-4(3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-4-(1-oxooctadecyl)-2-phenyl-)
• 122135-70-0(1,9-Nonanedione, 1,9-bis(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)-)